Related Experiment Video
Updated: Nov 28, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Rhabdomyolysis induced by paliperidone palmitate]
Beate Klein1, Christoph Silberbauer2
1Abteilung für Psychiatrie und Psychotherapeutische Medizin, Salzkammergut Klinikum Vöcklabruck, Dr.-Wilhelm-Bock-Straße 1, 4840, Vöcklabruck, Österreich. beate.klein@ooeg.at.
Abstract:
Rhabdomyolysis is defined by disintegration of skeletal muscle fibres. Clinical presentation varies and is mostly associated with myalgias as well as elevation of creatine kinase in the serum. Mechanical damage, toxic medicinal factors, and predisposing factors such as myopathies may trigger the condition. This report describes a case of rhabdomyolysis uncovered by chance after administration of paliperidonepalmitate as depot medication in a 45 years old schizophrenic male patient after having tolerated oral risperidone without any problems. Routine screening for clinical manifestations and serum-creatin kinase maybe essential in unravelling antipsychotic-induced rhabdomyolysis.
More Related Videos
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Hemodialysis II: Procedure and Complications
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Nephrotic Syndrome I : Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment